Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12222321 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL7664427 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL7598498 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL6430243 | 0.89 | POLB (0.42) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL7637083 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL2985756 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL2985752 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL30078422 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EMAPTKMT2AAPAF1 | |
| SCHEMBL6428029 | 0.80 | LAP3 (0.43) | PKM | |
| SCHEMBL6429966 | 0.79 | LAP3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155023-B1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO SPA (IT) | 2005-03-02 | — | — | EP | claimed |
| JP-2003518131-A | — | — | 2003-06-03 | — | — | JP | claimed |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2003-01-16 | — | — | US | claimed |
| EP-1155023-A1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.p.A. (IT) | 2001-11-21 | — | — | EP | claimed |
| WO-2001046207-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2001-06-28 | — | — | WO | claimed |
| EP-1155023-B1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO SPA (IT) | 2005-03-02 | — | — | EP | disclosed |
| US-6509324-B1 | Use as contrast agents in magnetic resonance imaging | BRACCO S.P.A. (IT) | 2003-01-21 | — | — | US | disclosed |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2003-01-16 | — | — | US | disclosed |
| EP-1155023-A1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.p.A. (IT) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001046207-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | MPI, SLC39A14, LRPPRC | SMN1; SMN2 2242/4885KDM4E 3431/4885MAPT 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.